ENXTPA:DIM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. More Details

Rewards

Earnings are forecast to grow 16.43% per year

Earnings have grown 17.4% per year over the past 5 years

Risk Analysis

No risks detected for DIM from our risk checks.


Snowflake Analysis

Excellent balance sheet with proven track record.


Similar Companies

Share Price & News

How has Sartorius Stedim Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DIM has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

5.4%

DIM

-0.3%

FR Life Sciences

-2.2%

FR Market


1 Year Return

148.1%

DIM

75.1%

FR Life Sciences

-9.6%

FR Market

Return vs Industry: DIM exceeded the French Life Sciences industry which returned 78.1% over the past year.

Return vs Market: DIM exceeded the French Market which returned -7.9% over the past year.


Shareholder returns

DIMIndustryMarket
7 Day5.4%-0.3%-2.2%
30 Day11.9%3.6%2.8%
90 Day25.7%11.6%0.01%
1 Year148.4%148.1%76.0%75.1%-7.6%-9.6%
3 Year463.7%456.6%124.5%119.6%2.9%-6.0%
5 Year522.7%506.9%276.5%252.4%29.3%10.1%

Price Volatility Vs. Market

How volatile is Sartorius Stedim Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sartorius Stedim Biotech undervalued compared to its fair value and its price relative to the market?

100.85x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: DIM (€326.2) is trading above our estimate of fair value (€100.45)

Significantly Below Fair Value: DIM is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DIM is poor value based on its PE Ratio (100.9x) compared to the XE Life Sciences industry average (60.2x).

PE vs Market: DIM is poor value based on its PE Ratio (100.9x) compared to the French market (18.5x).


Price to Earnings Growth Ratio

PEG Ratio: DIM is poor value based on its PEG Ratio (6.1x)


Price to Book Ratio

PB vs Industry: DIM is overvalued based on its PB Ratio (22.3x) compared to the XE Life Sciences industry average (5.5x).


Next Steps

Future Growth

How is Sartorius Stedim Biotech forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

16.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DIM's forecast earnings growth (16.4% per year) is above the savings rate (0.6%).

Earnings vs Market: DIM's earnings (16.4% per year) are forecast to grow slower than the French market (23.4% per year).

High Growth Earnings: DIM's earnings are forecast to grow, but not significantly.

Revenue vs Market: DIM's revenue (16.1% per year) is forecast to grow faster than the French market (6.8% per year).

High Growth Revenue: DIM's revenue (16.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DIM's Return on Equity is forecast to be high in 3 years time (21.8%)


Next Steps

Past Performance

How has Sartorius Stedim Biotech performed over the past 5 years?

17.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DIM has high quality earnings.

Growing Profit Margin: DIM's current net profit margins (17.1%) are lower than last year (17.7%).


Past Earnings Growth Analysis

Earnings Trend: DIM's earnings have grown by 17.4% per year over the past 5 years.

Accelerating Growth: DIM's earnings growth over the past year (20.9%) exceeds its 5-year average (17.4% per year).

Earnings vs Industry: DIM earnings growth over the past year (20.9%) underperformed the Life Sciences industry 28.5%.


Return on Equity

High ROE: DIM's Return on Equity (21.8%) is considered high.


Next Steps

Financial Health

How is Sartorius Stedim Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: DIM's short term assets (€961.1M) exceed its short term liabilities (€536.7M).

Long Term Liabilities: DIM's short term assets (€961.1M) exceed its long term liabilities (€447.2M).


Debt to Equity History and Analysis

Debt Level: DIM's debt to equity ratio (19.9%) is considered satisfactory.

Reducing Debt: DIM's debt to equity ratio has increased from 18.2% to 19.9% over the past 5 years.

Debt Coverage: DIM's debt is well covered by operating cash flow (150.8%).

Interest Coverage: DIM's interest payments on its debt are well covered by EBIT (41.5x coverage).


Balance Sheet


Next Steps

Dividend

What is Sartorius Stedim Biotech current dividend yield, its reliability and sustainability?

0.10%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: DIM's dividend (0.1%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.55%).

High Dividend: DIM's dividend (0.1%) is low compared to the top 25% of dividend payers in the French market (5.17%).


Stability and Growth of Payments

Stable Dividend: DIM is not paying a notable dividend for the French market, therefore no need to check if payments are stable.

Growing Dividend: DIM is not paying a notable dividend for the French market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: DIM is not paying a notable dividend for the French market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DIM's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average board tenure


CEO

Joachim Kreuzburg (55 yo)

no data

Tenure

€2,735,000

Compensation

Dr. rer. pol. Joachim Kreuzburg serves as the Chairman and Chief Executive Officer at Sartorius Stedim Biotech GmbH. Dr. rer. pol. Kreuzburg has been the Chairman of Executive Board at Sartorius Aktiengese ...


CEO Compensation Analysis

Compensation vs Market: Joachim's total compensation ($USD3.23M) is about average for companies of similar size in the French market ($USD4.01M).

Compensation vs Earnings: Joachim's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Joachim Kreuzburg
Chairman & CEOno data€2.74m0.000010%
€ 3.0k
Lothar Kappich
Non-Executive Director3.08yrs€55.00k0%
€ 0
Henri Riey
Non-Executive Director13.33yrs€46.40k0.000010%
€ 3.0k
Pascale Boissel
Independent Non Executive Director1.58yrs€37.30k0%
€ 0
Anne-Marie Graffin
Non-Executive Independent Director5.5yrs€45.50k0.000010%
€ 3.0k
Susan Dexter
Non-Executive Independent Director5.5yrs€37.70k0.000010%
€ 3.0k
René Fáber
Non Executive Director1.58yrsno data0%
€ 0
Amélie Buton
Employee Representative Non Executive Director1.08yrsno data0%
€ 0

3.1yrs

Average Tenure

57yo

Average Age

Experienced Board: DIM's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sartorius Stedim Biotech S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sartorius Stedim Biotech S.A.
  • Ticker: DIM
  • Exchange: ENXTPA
  • Founded: 1870
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €30.069b
  • Shares outstanding: 92.18m
  • Website: https://www.sartorius.com

Number of Employees


Location

  • Sartorius Stedim Biotech S.A.
  • Zone Industrielle Les Paluds
  • Avenue de Jouques – CS 91051
  • Aubagne
  • Provence-Alpes-Côte d'Azur
  • 13781
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DIMENXTPA (Euronext Paris)YesShare CapitalFREURJul 2007
0RG8LSE (London Stock Exchange)YesShare CapitalGBEURJul 2007
56S1DB (Deutsche Boerse AG)YesShare CapitalDEEURJul 2007
SDMH.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDJul 2007
DIMPBATS-CHIXE (BATS 'Chi-X Europe')YesShare CapitalGBEURJul 2007

Biography

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; biore ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 21:01
End of Day Share Price2020/10/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.